Is chemoradiation effective or harmful for stage VI gastric cancer patients?

Yoshiro Saikawa, Tetsuro Kubota, Tsunehiro Takahashi, Yukako Akatsu, Rieko Nakamura, Masashi Yoshida, Naoyuki Shigematsu, Yoshihide Otani, Koichiro Kumai, Toshifumi Hibi, Masaki Kitajima

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We aim to clarify beneficial effect of pre-operative radiation with chemotherapy in highly advanced gastric cancer patients, evaluating histological response, toxicity and patients' quality of life (QOL). We used pre-operative radiation with S-1 and low-dose cisplatin to treat 8 patients with highly advanced gastric cancer (clinical stage IV) in a pilot study. Clinical staging after therapy showed 5 PRs (partial response), 2 NCs (no change), and 1 PD (partial disease) following evaluation of the primary tumor and suspicious metastatic lesions in the lymph nodes, esophagus, liver, and peritoneum, for a response rate of 62.5% (5/8 cases). Of 8 patients, 6 underwent surgery, and 2 of these 6 patients had a histologically complete response (grade 3 effect) and 3 patients had a partial response (grade 2 effect), suggesting that a high histological response (5/6 cases; 83.3%) is expected by the chemoradiation. The survival analysis showed that 5 out of the 8 patients died within 10 months after initiating therapy, while 3 patients are alive without recurrence at 15, 18, and 30 months after therapy, suggesting a relatively good outcome for clinical stage IV gastric cancer. All cases showed grade 2-4 bone marrow suppression toxicity and/or grade 0-2 gastrointestinal toxicity, while 5 out of 8 patients (62.5%) showed improvement in appetite loss at the end of the therapy, indicating that the patients' quality of life (QOL) was preserved. Chemoradiation may be a powerful regimen for obtaining histological response with tolerable toxicity and improved QOL in highly advanced gastric cancer patients.

Original languageEnglish
Pages (from-to)865-870
Number of pages6
JournalOncology Reports
Volume13
Issue number5
Publication statusPublished - 2005 May

Fingerprint

Stomach Neoplasms
Quality of Life
Radiation
Peritoneum
Appetite
Therapeutics
Survival Analysis
Cisplatin
Esophagus
Lymph Nodes
Bone Marrow
Recurrence
Drug Therapy
Liver

Keywords

  • Cisplatin
  • Gastric cancer
  • Pre-operative chemoradiation
  • S-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Saikawa, Y., Kubota, T., Takahashi, T., Akatsu, Y., Nakamura, R., Yoshida, M., ... Kitajima, M. (2005). Is chemoradiation effective or harmful for stage VI gastric cancer patients? Oncology Reports, 13(5), 865-870.

Is chemoradiation effective or harmful for stage VI gastric cancer patients? / Saikawa, Yoshiro; Kubota, Tetsuro; Takahashi, Tsunehiro; Akatsu, Yukako; Nakamura, Rieko; Yoshida, Masashi; Shigematsu, Naoyuki; Otani, Yoshihide; Kumai, Koichiro; Hibi, Toshifumi; Kitajima, Masaki.

In: Oncology Reports, Vol. 13, No. 5, 05.2005, p. 865-870.

Research output: Contribution to journalArticle

Saikawa, Y, Kubota, T, Takahashi, T, Akatsu, Y, Nakamura, R, Yoshida, M, Shigematsu, N, Otani, Y, Kumai, K, Hibi, T & Kitajima, M 2005, 'Is chemoradiation effective or harmful for stage VI gastric cancer patients?', Oncology Reports, vol. 13, no. 5, pp. 865-870.
Saikawa Y, Kubota T, Takahashi T, Akatsu Y, Nakamura R, Yoshida M et al. Is chemoradiation effective or harmful for stage VI gastric cancer patients? Oncology Reports. 2005 May;13(5):865-870.
Saikawa, Yoshiro ; Kubota, Tetsuro ; Takahashi, Tsunehiro ; Akatsu, Yukako ; Nakamura, Rieko ; Yoshida, Masashi ; Shigematsu, Naoyuki ; Otani, Yoshihide ; Kumai, Koichiro ; Hibi, Toshifumi ; Kitajima, Masaki. / Is chemoradiation effective or harmful for stage VI gastric cancer patients?. In: Oncology Reports. 2005 ; Vol. 13, No. 5. pp. 865-870.
@article{1ecb797dd14d48b99f4b2a5bc5d25112,
title = "Is chemoradiation effective or harmful for stage VI gastric cancer patients?",
abstract = "We aim to clarify beneficial effect of pre-operative radiation with chemotherapy in highly advanced gastric cancer patients, evaluating histological response, toxicity and patients' quality of life (QOL). We used pre-operative radiation with S-1 and low-dose cisplatin to treat 8 patients with highly advanced gastric cancer (clinical stage IV) in a pilot study. Clinical staging after therapy showed 5 PRs (partial response), 2 NCs (no change), and 1 PD (partial disease) following evaluation of the primary tumor and suspicious metastatic lesions in the lymph nodes, esophagus, liver, and peritoneum, for a response rate of 62.5{\%} (5/8 cases). Of 8 patients, 6 underwent surgery, and 2 of these 6 patients had a histologically complete response (grade 3 effect) and 3 patients had a partial response (grade 2 effect), suggesting that a high histological response (5/6 cases; 83.3{\%}) is expected by the chemoradiation. The survival analysis showed that 5 out of the 8 patients died within 10 months after initiating therapy, while 3 patients are alive without recurrence at 15, 18, and 30 months after therapy, suggesting a relatively good outcome for clinical stage IV gastric cancer. All cases showed grade 2-4 bone marrow suppression toxicity and/or grade 0-2 gastrointestinal toxicity, while 5 out of 8 patients (62.5{\%}) showed improvement in appetite loss at the end of the therapy, indicating that the patients' quality of life (QOL) was preserved. Chemoradiation may be a powerful regimen for obtaining histological response with tolerable toxicity and improved QOL in highly advanced gastric cancer patients.",
keywords = "Cisplatin, Gastric cancer, Pre-operative chemoradiation, S-1",
author = "Yoshiro Saikawa and Tetsuro Kubota and Tsunehiro Takahashi and Yukako Akatsu and Rieko Nakamura and Masashi Yoshida and Naoyuki Shigematsu and Yoshihide Otani and Koichiro Kumai and Toshifumi Hibi and Masaki Kitajima",
year = "2005",
month = "5",
language = "English",
volume = "13",
pages = "865--870",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Is chemoradiation effective or harmful for stage VI gastric cancer patients?

AU - Saikawa, Yoshiro

AU - Kubota, Tetsuro

AU - Takahashi, Tsunehiro

AU - Akatsu, Yukako

AU - Nakamura, Rieko

AU - Yoshida, Masashi

AU - Shigematsu, Naoyuki

AU - Otani, Yoshihide

AU - Kumai, Koichiro

AU - Hibi, Toshifumi

AU - Kitajima, Masaki

PY - 2005/5

Y1 - 2005/5

N2 - We aim to clarify beneficial effect of pre-operative radiation with chemotherapy in highly advanced gastric cancer patients, evaluating histological response, toxicity and patients' quality of life (QOL). We used pre-operative radiation with S-1 and low-dose cisplatin to treat 8 patients with highly advanced gastric cancer (clinical stage IV) in a pilot study. Clinical staging after therapy showed 5 PRs (partial response), 2 NCs (no change), and 1 PD (partial disease) following evaluation of the primary tumor and suspicious metastatic lesions in the lymph nodes, esophagus, liver, and peritoneum, for a response rate of 62.5% (5/8 cases). Of 8 patients, 6 underwent surgery, and 2 of these 6 patients had a histologically complete response (grade 3 effect) and 3 patients had a partial response (grade 2 effect), suggesting that a high histological response (5/6 cases; 83.3%) is expected by the chemoradiation. The survival analysis showed that 5 out of the 8 patients died within 10 months after initiating therapy, while 3 patients are alive without recurrence at 15, 18, and 30 months after therapy, suggesting a relatively good outcome for clinical stage IV gastric cancer. All cases showed grade 2-4 bone marrow suppression toxicity and/or grade 0-2 gastrointestinal toxicity, while 5 out of 8 patients (62.5%) showed improvement in appetite loss at the end of the therapy, indicating that the patients' quality of life (QOL) was preserved. Chemoradiation may be a powerful regimen for obtaining histological response with tolerable toxicity and improved QOL in highly advanced gastric cancer patients.

AB - We aim to clarify beneficial effect of pre-operative radiation with chemotherapy in highly advanced gastric cancer patients, evaluating histological response, toxicity and patients' quality of life (QOL). We used pre-operative radiation with S-1 and low-dose cisplatin to treat 8 patients with highly advanced gastric cancer (clinical stage IV) in a pilot study. Clinical staging after therapy showed 5 PRs (partial response), 2 NCs (no change), and 1 PD (partial disease) following evaluation of the primary tumor and suspicious metastatic lesions in the lymph nodes, esophagus, liver, and peritoneum, for a response rate of 62.5% (5/8 cases). Of 8 patients, 6 underwent surgery, and 2 of these 6 patients had a histologically complete response (grade 3 effect) and 3 patients had a partial response (grade 2 effect), suggesting that a high histological response (5/6 cases; 83.3%) is expected by the chemoradiation. The survival analysis showed that 5 out of the 8 patients died within 10 months after initiating therapy, while 3 patients are alive without recurrence at 15, 18, and 30 months after therapy, suggesting a relatively good outcome for clinical stage IV gastric cancer. All cases showed grade 2-4 bone marrow suppression toxicity and/or grade 0-2 gastrointestinal toxicity, while 5 out of 8 patients (62.5%) showed improvement in appetite loss at the end of the therapy, indicating that the patients' quality of life (QOL) was preserved. Chemoradiation may be a powerful regimen for obtaining histological response with tolerable toxicity and improved QOL in highly advanced gastric cancer patients.

KW - Cisplatin

KW - Gastric cancer

KW - Pre-operative chemoradiation

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=18544372370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18544372370&partnerID=8YFLogxK

M3 - Article

C2 - 15809751

AN - SCOPUS:18544372370

VL - 13

SP - 865

EP - 870

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -